| Qiagen–Tecan: lab automation, 201903– collab direct supply of Tecan Fluent workstation for sample to labs using QuantiFeron-TB Gold Plus test |
2019-03-08 |
| Gilde Investment–SEVERAL: investment, 201903 final close €200m Gilde Healthcare Service III fund incl PGGM/PF Zorg en Welzijn + Rabo Corp Investments |
2019-03-07 |
| BPCE–SEVERAL: investment, 201903 first closing €na of Seventure Health for Life Capital II Fund with final target size of over €200m |
2019-03-05 |
| Novasep–Sartorius: chromatography, 201903– collab developm of systems for membrane chromatography SSB |
2019-03-05 |
| abcr GmbH–Enzymicals: enzymes, 201903– collab distribution expansion ww sale of all catalogue products of Enzymcials by acbr |
2019-03-04 |
| NovaGo Therapeutics–Bellevue: investment, 201903 financing round Series A totalling CHF10m incl co-lead investor Pureos Bioventures |
2019-03-04 |
| NovaGo Therapeutics–Neurimmune: investment, 201903 financing round Series A totalling CHF10m incl co-lead investor + strategic partner Neurimmune |
2019-03-04 |
| NovaGo Therapeutics–SEVERAL: investment, 201903 financing round Series A CHF10m co-led by Pureos Bioventures + Neurimmune |
2019-03-04 |
| BioKryo–Air Liquide: investment, 201903c acquisition of BioKryo by Air Liquide |
2019-03-01 |
| CEPI–CureVac: mRNA vaccine production technology, 201903–202202 collab up to $34m developm of mobile mRNA printing facility |
2019-03-01 |
| Humedics–BPCE: investment, 201903 existent portfolio company of Seventure Partners |
2019-03-01 |
| TU Dresden–Germany (govt): grant, 201903–202212 GO-Bio Phase I grant €3.9m for RecTech project from BMBF |
2019-03-01 |
| iOnctura–Optimum Strategic Communications: public relations, 201902 service existent by Optimum |
2019-02-28 |
| Sarepta–Centogene: molecular diagnostics, 201902–202002 collab service identifying DMD patients in MENA region by Centogene |
2019-02-28 |
| Versum Materials–Merck (DE): investment, 201902– unsolicited all-cash offer at $48/share by Merck |
2019-02-27 |
| Anaveon–Novartis: investment, 201902 financing round Series A totalling CHF35m incl co-investor Novartis Venture Fund |
2019-02-26 |
| Anaveon–SEVERAL: investment, 201902 financing round Series A CHF35m incl CHF28m from lead investor Syncona Ltd |
2019-02-26 |
| Anaveon–Wellcome Trust: investment, 201902 financing round Series A totalling CHF35m incl CHF28m from lead investor Syncona Ltd |
2019-02-26 |
| Hookipa–Invus Group: investment, 201902 financing round Series D totalling €33.2m incl new + co-investor Invus |
2019-02-26 |
| Hookipa–Redmile Group: investment, 201902 financing round Series D totalling €33.2m incl new + lead investor Redmile Group |
2019-02-26 |
| Hookipa–Samsara BioCapital: investment, 201902 financing round Series D totalling €33.2m incl new + co-investor Samsara BioCapital |
2019-02-26 |
| Hookipa–SEVERAL: investment, 201902 financing round Series D €33.2m ($37.4m) led by Redmile Group + incl Invus + Samsara Capital et al. |
2019-02-26 |
| Samsara Therapeutics–Apollo Health Ventures: investment, 201902 seed financing round totalling €1m incl lead investor Apollo Ventures |
2019-02-26 |
| Samsara Therapeutics–Evotec: medicinal chemistry, 201902 supply service existent compound optimisationn by Evotec |
2019-02-26 |
| Samsara Therapeutics–SEVERAL: investment, 201902 seed financing round €1m led by Apollo Ventures |
2019-02-26 |
| General Electric–Danaher: investment, 201902–202003 acquisition $21.4b in cash of biopharma business of GE Life Sciences |
2019-02-25 |
| Roche–Citigroup: financial services, 201902 supply Citi financial advisor to Roche with regard to acquisition of Spark by Roche |
2019-02-25 |
| Roche–Davis Polk & Wardwell: legal services, 201902 supply service legal advisor to Roche w regard acquisition of Spark Therapeutics |
2019-02-25 |
| Spark Therapeutics–Centerview Partners: financial services, 201902 supply financial advisor to Spark with regard to acquisition of Spark by Roche |
2019-02-25 |
| Spark Therapeutics–Cowen: financial services, 201902 supply financial advisor to Spark with regard to acquisition of Spark by Roche |
2019-02-25 |
| Spark Therapeutics–Goodwin Procter: legal services, 201902 supply legal counsel to Spark with regard to acquisition of Spark by Roche |
2019-02-25 |
| Spark Therapeutics–Roche: investment, 201902–201912 acquisition $4.3b cash tender offer for all shares at $114.5/share |
2019-02-25 |
| Alchemist Accelerator–BASF: investment, 201902 BASF Venture Capital invests $2m + becomes Limited Partner |
2019-02-20 |
| Calypso Biotech–ABP (NL): investment, 201902 financing round Series A totalling €20m incl co-lead investor Inkef Capital |
2019-02-20 |
| Calypso Biotech–Gilde Investment: investment, 201902 financing round Series A totalling €20m incl co-lead investor Gilde Healthcare |
2019-02-20 |
| Calypso Biotech–JnJ: investment, 201902 financing round Series A totalling €20m incl co-investor JnJ Innovation JJDC |
2019-02-20 |
| Calypso Biotech–Merck (DE): investment, 201902 financing round Series A totalling €20m incl co- + founding investor M Ventures |
2019-02-20 |
| Calypso Biotech–SEVERAL: investment, 201902 financing round Series A €20m co-led by Gilde Healthcare + Inkef Capital |
2019-02-20 |
| Evotec–Helmholtz: antibiotics, 201902– collab development with initial focus on cystobactamids with Helmholtz HZI Braunschweig |
2019-02-20 |
| CRISPR Therapeutics–StrideBio: AAV vectors, 201902– collab expansion €na of developm + license option usingStrideBio’s vectors for CRISPR therapies |
2019-02-19 |
| Gain Therapeutics–Fondazione Centenario BancaStato: investment, 201902 financing round Series A totalling €2.5m incl €400k from TiVenture SA |
2019-02-19 |
| Gain Therapeutics–Helsinn: investment, 201902 financing round Series A totalling €2.5m incl €1m from new investor Helsinn Investment Fund SA |
2019-02-19 |
| Gain Therapeutics–SEVERAL: investment, 201902 financing round Series A €2.5m from VitaTech + Helsinn Investment Fund + TiVenture |
2019-02-19 |
| Gain Therapeutics–VitaTech: investment, 201902 financing round Series A totalling €2.5m incl €1.1m from new investor VitaTech SA |
2019-02-19 |
| Qiagen–Curetis: bioinformatics, 201902– license excl to use ARESdb for general bioinformatics research offerings + services for AMR research |
2019-02-18 |
| S-Biomedic–DSM: investment, 201902 financing round Series A 2nd closing totalling €2m incl new investor DSM Venturing |
2019-02-18 |
| S-Biomedic–SEVERAL: investment, 201902 financing round Series A 2nd closing €2m from new investor DSM Venturing + existing investor investiere.ch |
2019-02-18 |
| S-Biomedic–Verve Capital Partners: investment, 201902 financing round Series A 2nd closing totalling €2m incl existing investor investiere.ch |
2019-02-18 |
| Arvelle Therapeutics–Andera Partners: investment, 201902 financing round Series A totalling $180m incl investor Andera Partners |
2019-02-14 |
| Arvelle Therapeutics–BRV Capital: investment, 201902 financing round Series A totalling $180m incl investor BRV Capital Management |
2019-02-14 |
| Arvelle Therapeutics–H.I.G. Capital: investment, 201902 financing round Series A totalling $180m incl investor H.I.G. BioHealth Partners |
2019-02-14 |
| Arvelle Therapeutics–Life Sciences Partners: investment, 201902 financing round Series A totalling $180m incl lead investor LSP |
2019-02-14 |
| Arvelle Therapeutics–NovaQuest Capital: investment, 201902 financing round Series A totalling $180m incl investor NovaQuest Capital Management |
2019-02-14 |
| Arvelle Therapeutics–Sam Brown: public relations, 201902 service existent by Sam Brown Inc |
2019-02-14 |
| Arvelle Therapeutics–SEVERAL: investment, 201902–202005 financing round Series A $180m with global investor syndicate |
2019-02-14 |
| Arvelle Therapeutics–SK Group: cenobamate, 201902– license excl for Europe $110m upfront + $430m milestones + royalties from SK Biopharmaceuticals |
2019-02-14 |
| Novartis–AbCellera: therapeutic antibodies, 201902– collab discovery use of AbCellera technology + screening for up to ten targets |
2019-02-14 |
| Plasmion–Bavaria (govt): investment, 201902 financing round totalling almost €1m from HTGF + BayBG + business angel |
2019-02-14 |
| Plasmion–High-Tech Gründerfonds: investment, 201902 financing round totalling almost €1m from HTGF + BayBG + business angel |
2019-02-14 |
| Plasmion–PERSON: investment, 201902 financing round totalling almost €1m from HTGF + BayBG + business angel |
2019-02-14 |
| Plasmion–SEVERAL: investment, 201902 financing round almost €1m from HTGF + BayBG + business angel |
2019-02-14 |
| Boehringer–IBM: blockchain technology, 201902– collab to integrate blockchain technology into clinical trials of BI Canada + IBM Canada |
2019-02-12 |
| Andrew Alliance–Sartorius: electronic pipettes, 201902 collab co-developm + launch Pipette+ system combining Picus hardware with OneLab s/w |
2019-02-08 |
| Symrise–SEVERAL: investment, 201902 capital increase €400m with 5.614m new shares at €71.25/share to fund acquisition of ADF/IDF |
2019-02-08 |
| Galapagos–Evotec: antifibrotic, 201902– collab + ww commercial rights for Galapagos to small-molecule programme for fibrotic diseases |
2019-02-07 |
| Denothex–Optimapharm: investment, 201902 acquisition of Denothex Ltd by Optimapharm |
2019-02-06 |
| Waters–Andrew Alliance: automated liquid handling technology, 201902–collab new solutions for LC-MS research |
2019-02-06 |
| Bruker–Genedata: bioinformatics, 201902 collab product integration Bruker new Ready-to-Run partner |
2019-02-05 |
| Numares–Mayo Clinic: NMR spectroscopy, 201902– collab developm metabolomics-based NMR clinical tests with Mayo Clinic Labs |
2019-02-05 |
| Roche–Xencor: cancer immunotherapy, 201901– collab developm + commerc ww $120m upfront + milestones + profit share IL-15 cytokine drugs Genentech |
2019-02-05 |
| Macherey-Nagel–Andrew Alliance: automated liquid handling technology, 201902–collab co-marketing NucleoBond kits with OneLab s/w + Andrew+ robot |
2019-02-04 |
| United Kingdom (govt)–Qiagen: bioinformatics, 201902– supply Genomics England selects QCI for genome sequencing project of NHS |
2019-02-04 |
| ADF/IDF–Symrise: investment, 201901– acquisition $900m by Symrise ANNOUNCED |
2019-01-31 |
| Apceth–Hitachi: investment, 201901–201904 acquisition €75.5m 100% of Apceth Biopharma GmbH from Apceth GmbH by Hitachi Chemical |
2019-01-31 |
| Bayer–Univ Kyoto: drug discovery, 201901– collab €na research alliance for drug target discovery for pulmonary diseases incl IPF |
2019-01-31 |
| Dewpoint Therapeutics–6 Dimensions Capital: investment, 201901 financing round Series A totalling $60m incl co-investor 6 Dimensions Capital |
2019-01-30 |
| Dewpoint Therapeutics–Alexandria Real Estate: investment, 201901 financing round Series A totalling $60m incl co-investor Alexandria Ventures |
2019-01-30 |
| Dewpoint Therapeutics–Bayer: investment, 201901 financing round Series A totalling $60m incl co-investor Leaps by Bayer |
2019-01-30 |
| Dewpoint Therapeutics–EcoR1 Capital: investment, 201901 financing round Series A totalling $60m incl co-investor EcoR1 Capital |
2019-01-30 |
| Dewpoint Therapeutics–Polaris Partners: investment, 201901 financing round Series A totalling $60m incl lead investor Polaris Partners |
2019-01-30 |
| Dewpoint Therapeutics–Samsara BioCapital: investment, 201901 financing round Series A totalling $60m incl co-investor Samsara BioCapital |
2019-01-30 |
| Dewpoint Therapeutics–SEVERAL: investment, 201901 financing round Series A $60m led by Polaris Partners |
2019-01-30 |
| Medizinsches Labor Hannover–Labor Limbach: investment, 201901 acquisition 100% of MLH by Limbach Gruppe SE PENDING |
2019-01-26 |
| MAB Discovery–BioNTech: investment, 201901–201903 acquisition €na of Antibody Generation Unit of MAB Discovery by BioNTech |
2019-01-23 |
| CRISPR Therapeutics–Minapharm: gene transfer technology, 201901– collab + license €na with ProBioGen to develop in vivo delivery technology for CRISPR |
2019-01-22 |
| Scailyte–SEVERAL: investment, 201901 seed financing round CHF2.75m incl new investors Swisscom Ventures + Zürcher Kantonalbank |
2019-01-22 |
| Scailyte–Swisscom: investment, 201901 seed financing round totalling CHF2.75m incl new investors Swisscom Ventures + Zürcher Kantonalbank |
2019-01-22 |
| Scailyte–Zürcher Kantonalbank: investment, 201901 seed financing round totalling CHF2.75m incl new investors Swisscom Ventures + Zürcher Kantonalbank |
2019-01-22 |
| Link Health–Marinomed: drug delivery technology, 201901– collab registration + distribution of Marinosolv products in China by Link Health |
2019-01-21 |
| Medison Pharma–Alnylam: RNAi therapeutics, 201901– commcercialisation excl of Onpattro + other RNAi drugs from Alnylam in Israel |
2019-01-21 |
| Miltenyi Biotec–Univ Duisburg-Essen: imaging technology, 201901 acquisition process for opitcal clearing of biological samples for miccrosopy |
2019-01-17 |
| Mologen–SEVERAL: credit, 201901–202701 convertible bonds €2.7m at 6% incl existing shareholders |
2019-01-17 |
| Mecuris–Bavaria (govt): investment, 201901 financing round Series A totalling €3.6m incl existing investor Bayern Kapital GmbH |
2019-01-16 |
| Mecuris–High-Tech Gründerfonds: investment, 201901 financing round Series A totalling €3.6m incl existing investor HTGF |
2019-01-16 |
| Mecuris–Mulcan: investment, 201901 financing round Series A totalling €3.6m incl new investor MII Mulcan International Investments GmbH |
2019-01-16 |
| Mecuris–OTHER: investment, 201901 financing round Series A totalling €3.6m incl new investor one of largest German hospital chains |
2019-01-16 |
| Mecuris–SEVERAL: investment, 201901 financing round Series A €3.6m incl Bayern Kapital + HTGF + Vesalius Biocapital + Mulcan et al. |
2019-01-16 |
| Mecuris–Vesalius Biocapital: investment, 201901 financing round Series A totalling €3.6m incl new investor Vesalius Biocapital III SICAR |
2019-01-16 |
| United States (govt)–Valneva: Japanese encephalitis vaccine, 201901– supply $59m+$11m of Ixiaro to US DoD |
2019-01-16 |
| Boehringer–Bioharmony Therapeutics: antibiotics, 201901– collab developm of bateriophage lysins |
2019-01-15 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo.svg){kind=logo}
1 2 3 ... 28 29 30 ... 42 43 44 
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
